Frontier Science collaborated with the Breast International Group (BIG) on the ALTTO and Neo-ALTTO trials. These trials were built on the results from the successful HERA trial and aimed to study the benefit of adding Lapatinib to Herceptin® in both adjuvant and neo-adjuvant treatment regimens for breast cancer.
Frontier Science was responsible for randomisation, various aspects of project management, data quality control and for statistical programming and analysis. These trials involved participation of breast cancer trials groups and independent sites around the world, including North America. Neo-ALTTO reported its primary analysis in The Lancet in 2012 and ALTTO in the Journal of Clinical Oncology in 2015. The trials have now completed their follow-up analyses and Frontier Science is collaborating in the write up of the 10 year follow-up results for both trials.